摘要
缺血修饰白蛋白(IMA)是美国食品与药物管理局批准的第一个心肌缺血生化标志物,IMA可对急性心肌缺血做出早期诊断,且明显提高对急性冠状动脉综合征早期诊断敏感性。目前,我国在该领域的研究尚处于起步阶段,对IMA检验方法的评价及改进、国人参考值范围的确立,以及在心脏损伤中应用的评价还有待进一步研究。
Ischemia modified albumin is the first biochemical marker of myocardial ischemia approved by FDA. IMA may make an early diagnosis of acute coronary ischemia,and will improve the early diagnostic sensitivity of acute comary syndrome significantly. At present our country is at the start stage in this domain research. Many questions need further studying, such as the evaluation and promotion of detective method of IMA the establishment of reference value for Chinese,and the applicational evaluation in heart injury,
出处
《医学综述》
2008年第10期1444-1446,共3页
Medical Recapitulate
基金
天津市卫生局科研基金资助项目(04KJ64)
